Characteristics of an ideal agent for the treatment of anemia in CKD

Targeting the underlying cause of anemia: Ideally, the agent should work by targeting the underlying causes of anemia, such as decreased erythropoietin (EPO) production and iron deficiency rather than simply increasing erythropoiesis. Efficacy: The agent should be effective at increasing hemoglobin levels and improving anemia-related symptoms in patients with CKD. Safety: The agent should be safe and have a favorable benefit-risk profile with minimal risk of serious side effects such as cardiovascular events and cancers. Convenience of use: The agent should be easy to administer with minimal monitoring requirements and few or no dietary restrictions. Cost-effective: The agent should be cost-effective and affordable for patients and not require prolonged treatment. Preservation of kidney function: The agent should not negatively impact on the kidney function, and if possible, should improve it.